General MedicationsVIALStandard
SYNAGIS
PALIVIZUMAB
Standard Dose
100MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SYNAGIS is listed in Drugs@FDA under application 103770 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient PALIVIZUMAB Form and strength VIAL - 100MG/VIAL Sponsor SWEDISH ORPHAN Submission history Latest submission status date: 2017-05-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview SYNAGIS is listed in Drugs@FDA under application 103770 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient PALIVIZUMAB Form and strength VIAL - 100MG/VIAL Sponsor SWEDISH ORPHAN Submission history Latest submission status date: 2017-05-12 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.